Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Heat Shock who wrote (141)	11/6/2000 7:43:15 PM
From: Heat Shock	Read Replies (1) of 236

To all: StressGen has initiated patient treatment in a phase III clinical trial to investigate HspE7 as a novel immunotherapeutic for anal dysplasia (AIN) caused by the human papilloma virus (HPV). quote.canada-stockwatch.com Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next